Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study
Background Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5–10% of women of reproductive age. The syndrome is surrounded by controversies regarding both its diagnosis and treatment. The introduction of long-acting GnRH agonists in the late 1980s revolutionized...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Behery, Mohamed Atef [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s) 2019 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Middle East Fertility Society journal - [S.l.] : Elsevier, 2004, 24(2019), 1 vom: 05. Sept. |
|---|---|
| Übergeordnetes Werk: |
volume:24 ; year:2019 ; number:1 ; day:05 ; month:09 |
| Links: |
|---|
| DOI / URN: |
10.1186/s43043-019-0002-1 |
|---|
| Katalog-ID: |
SPR038849267 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR038849267 | ||
| 003 | DE-627 | ||
| 005 | 20230519164958.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s43043-019-0002-1 |2 doi | |
| 035 | |a (DE-627)SPR038849267 | ||
| 035 | |a (SPR)s43043-019-0002-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Behery, Mohamed Atef |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2019 | ||
| 520 | |a Background Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5–10% of women of reproductive age. The syndrome is surrounded by controversies regarding both its diagnosis and treatment. The introduction of long-acting GnRH agonists in the late 1980s revolutionized the approach to ovarian stimulation in assisted reproductive technologies by providing the means to downregulate endogenous pituitary gonadotropin secretion and thereby prevent a premature luteinizing hormone surge during exogenous gonadotropin stimulation. The relatively recent introduction of GnRH antagonists in clinical practice has provided another option for ovarian stimulation in IVF. The purpose of this study was to compare the efficacy of the fixed GnRH antagonist vs. GnRH agonist long protocol in patients with polycystic ovary syndrome treated by ICSI. Results There is a statistically significant difference between both groups in view of the received dose of gonadotrophin (1901.7 ± 400.6 vs. 1789 ± 368 with p = .004) and duration of stimulation (11.3 ± 0.8 vs. 10.3 ± 1.1 with p = .017). There is no significant difference between both groups in view of pregnancy outcome (37% vs. 32% with p = .125). There is a significant difference between both groups in view of ovarian hyperstimulation syndrome (OHSS) incidence where the rates were 15%, 6%, and 1.5% vs. 4.5%, 2.5%, and .05% with p = 0.04 for mild, moderate, and severe, respectively, form of OHSS in group 1 and group 2. Conclusion The antagonist protocol may be the preferred stimulation protocol for PCOS patients treated by ICSI in view of the reduction of OHSS incidence rates without compromising the pregnancy outcome. | ||
| 650 | 4 | |a PCO |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a GnRH agonist |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a GnRH antagonist |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a ICSI |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a OHSS |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Hasan, Eman Anwar |4 aut | |
| 700 | 1 | |a Ali, Eman Ahmed |4 aut | |
| 700 | 1 | |a Eltabakh, Ahmed Abdelkader |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Middle East Fertility Society journal |d [S.l.] : Elsevier, 2004 |g 24(2019), 1 vom: 05. Sept. |w (DE-627)494831642 |w (DE-600)2196955-3 |x 2090-3251 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2019 |g number:1 |g day:05 |g month:09 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s43043-019-0002-1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_4305 | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2019 |e 1 |b 05 |c 09 | ||
| author_variant |
m a b ma mab e a h ea eah e a a ea eaa a a e aa aae |
|---|---|
| matchkey_str |
article:20903251:2019----::oprtvsuyeweaoitnatgnspooosncsainsnegi |
| hierarchy_sort_str |
2019 |
| publishDate |
2019 |
| allfields |
10.1186/s43043-019-0002-1 doi (DE-627)SPR038849267 (SPR)s43043-019-0002-1-e DE-627 ger DE-627 rakwb eng Behery, Mohamed Atef verfasserin aut Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2019 Background Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5–10% of women of reproductive age. The syndrome is surrounded by controversies regarding both its diagnosis and treatment. The introduction of long-acting GnRH agonists in the late 1980s revolutionized the approach to ovarian stimulation in assisted reproductive technologies by providing the means to downregulate endogenous pituitary gonadotropin secretion and thereby prevent a premature luteinizing hormone surge during exogenous gonadotropin stimulation. The relatively recent introduction of GnRH antagonists in clinical practice has provided another option for ovarian stimulation in IVF. The purpose of this study was to compare the efficacy of the fixed GnRH antagonist vs. GnRH agonist long protocol in patients with polycystic ovary syndrome treated by ICSI. Results There is a statistically significant difference between both groups in view of the received dose of gonadotrophin (1901.7 ± 400.6 vs. 1789 ± 368 with p = .004) and duration of stimulation (11.3 ± 0.8 vs. 10.3 ± 1.1 with p = .017). There is no significant difference between both groups in view of pregnancy outcome (37% vs. 32% with p = .125). There is a significant difference between both groups in view of ovarian hyperstimulation syndrome (OHSS) incidence where the rates were 15%, 6%, and 1.5% vs. 4.5%, 2.5%, and .05% with p = 0.04 for mild, moderate, and severe, respectively, form of OHSS in group 1 and group 2. Conclusion The antagonist protocol may be the preferred stimulation protocol for PCOS patients treated by ICSI in view of the reduction of OHSS incidence rates without compromising the pregnancy outcome. PCO (dpeaa)DE-He213 GnRH agonist (dpeaa)DE-He213 GnRH antagonist (dpeaa)DE-He213 ICSI (dpeaa)DE-He213 OHSS (dpeaa)DE-He213 Hasan, Eman Anwar aut Ali, Eman Ahmed aut Eltabakh, Ahmed Abdelkader aut Enthalten in Middle East Fertility Society journal [S.l.] : Elsevier, 2004 24(2019), 1 vom: 05. Sept. (DE-627)494831642 (DE-600)2196955-3 2090-3251 nnns volume:24 year:2019 number:1 day:05 month:09 https://dx.doi.org/10.1186/s43043-019-0002-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_206 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 24 2019 1 05 09 |
| spelling |
10.1186/s43043-019-0002-1 doi (DE-627)SPR038849267 (SPR)s43043-019-0002-1-e DE-627 ger DE-627 rakwb eng Behery, Mohamed Atef verfasserin aut Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2019 Background Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5–10% of women of reproductive age. The syndrome is surrounded by controversies regarding both its diagnosis and treatment. The introduction of long-acting GnRH agonists in the late 1980s revolutionized the approach to ovarian stimulation in assisted reproductive technologies by providing the means to downregulate endogenous pituitary gonadotropin secretion and thereby prevent a premature luteinizing hormone surge during exogenous gonadotropin stimulation. The relatively recent introduction of GnRH antagonists in clinical practice has provided another option for ovarian stimulation in IVF. The purpose of this study was to compare the efficacy of the fixed GnRH antagonist vs. GnRH agonist long protocol in patients with polycystic ovary syndrome treated by ICSI. Results There is a statistically significant difference between both groups in view of the received dose of gonadotrophin (1901.7 ± 400.6 vs. 1789 ± 368 with p = .004) and duration of stimulation (11.3 ± 0.8 vs. 10.3 ± 1.1 with p = .017). There is no significant difference between both groups in view of pregnancy outcome (37% vs. 32% with p = .125). There is a significant difference between both groups in view of ovarian hyperstimulation syndrome (OHSS) incidence where the rates were 15%, 6%, and 1.5% vs. 4.5%, 2.5%, and .05% with p = 0.04 for mild, moderate, and severe, respectively, form of OHSS in group 1 and group 2. Conclusion The antagonist protocol may be the preferred stimulation protocol for PCOS patients treated by ICSI in view of the reduction of OHSS incidence rates without compromising the pregnancy outcome. PCO (dpeaa)DE-He213 GnRH agonist (dpeaa)DE-He213 GnRH antagonist (dpeaa)DE-He213 ICSI (dpeaa)DE-He213 OHSS (dpeaa)DE-He213 Hasan, Eman Anwar aut Ali, Eman Ahmed aut Eltabakh, Ahmed Abdelkader aut Enthalten in Middle East Fertility Society journal [S.l.] : Elsevier, 2004 24(2019), 1 vom: 05. Sept. (DE-627)494831642 (DE-600)2196955-3 2090-3251 nnns volume:24 year:2019 number:1 day:05 month:09 https://dx.doi.org/10.1186/s43043-019-0002-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_206 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 24 2019 1 05 09 |
| allfields_unstemmed |
10.1186/s43043-019-0002-1 doi (DE-627)SPR038849267 (SPR)s43043-019-0002-1-e DE-627 ger DE-627 rakwb eng Behery, Mohamed Atef verfasserin aut Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2019 Background Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5–10% of women of reproductive age. The syndrome is surrounded by controversies regarding both its diagnosis and treatment. The introduction of long-acting GnRH agonists in the late 1980s revolutionized the approach to ovarian stimulation in assisted reproductive technologies by providing the means to downregulate endogenous pituitary gonadotropin secretion and thereby prevent a premature luteinizing hormone surge during exogenous gonadotropin stimulation. The relatively recent introduction of GnRH antagonists in clinical practice has provided another option for ovarian stimulation in IVF. The purpose of this study was to compare the efficacy of the fixed GnRH antagonist vs. GnRH agonist long protocol in patients with polycystic ovary syndrome treated by ICSI. Results There is a statistically significant difference between both groups in view of the received dose of gonadotrophin (1901.7 ± 400.6 vs. 1789 ± 368 with p = .004) and duration of stimulation (11.3 ± 0.8 vs. 10.3 ± 1.1 with p = .017). There is no significant difference between both groups in view of pregnancy outcome (37% vs. 32% with p = .125). There is a significant difference between both groups in view of ovarian hyperstimulation syndrome (OHSS) incidence where the rates were 15%, 6%, and 1.5% vs. 4.5%, 2.5%, and .05% with p = 0.04 for mild, moderate, and severe, respectively, form of OHSS in group 1 and group 2. Conclusion The antagonist protocol may be the preferred stimulation protocol for PCOS patients treated by ICSI in view of the reduction of OHSS incidence rates without compromising the pregnancy outcome. PCO (dpeaa)DE-He213 GnRH agonist (dpeaa)DE-He213 GnRH antagonist (dpeaa)DE-He213 ICSI (dpeaa)DE-He213 OHSS (dpeaa)DE-He213 Hasan, Eman Anwar aut Ali, Eman Ahmed aut Eltabakh, Ahmed Abdelkader aut Enthalten in Middle East Fertility Society journal [S.l.] : Elsevier, 2004 24(2019), 1 vom: 05. Sept. (DE-627)494831642 (DE-600)2196955-3 2090-3251 nnns volume:24 year:2019 number:1 day:05 month:09 https://dx.doi.org/10.1186/s43043-019-0002-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_206 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 24 2019 1 05 09 |
| allfieldsGer |
10.1186/s43043-019-0002-1 doi (DE-627)SPR038849267 (SPR)s43043-019-0002-1-e DE-627 ger DE-627 rakwb eng Behery, Mohamed Atef verfasserin aut Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2019 Background Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5–10% of women of reproductive age. The syndrome is surrounded by controversies regarding both its diagnosis and treatment. The introduction of long-acting GnRH agonists in the late 1980s revolutionized the approach to ovarian stimulation in assisted reproductive technologies by providing the means to downregulate endogenous pituitary gonadotropin secretion and thereby prevent a premature luteinizing hormone surge during exogenous gonadotropin stimulation. The relatively recent introduction of GnRH antagonists in clinical practice has provided another option for ovarian stimulation in IVF. The purpose of this study was to compare the efficacy of the fixed GnRH antagonist vs. GnRH agonist long protocol in patients with polycystic ovary syndrome treated by ICSI. Results There is a statistically significant difference between both groups in view of the received dose of gonadotrophin (1901.7 ± 400.6 vs. 1789 ± 368 with p = .004) and duration of stimulation (11.3 ± 0.8 vs. 10.3 ± 1.1 with p = .017). There is no significant difference between both groups in view of pregnancy outcome (37% vs. 32% with p = .125). There is a significant difference between both groups in view of ovarian hyperstimulation syndrome (OHSS) incidence where the rates were 15%, 6%, and 1.5% vs. 4.5%, 2.5%, and .05% with p = 0.04 for mild, moderate, and severe, respectively, form of OHSS in group 1 and group 2. Conclusion The antagonist protocol may be the preferred stimulation protocol for PCOS patients treated by ICSI in view of the reduction of OHSS incidence rates without compromising the pregnancy outcome. PCO (dpeaa)DE-He213 GnRH agonist (dpeaa)DE-He213 GnRH antagonist (dpeaa)DE-He213 ICSI (dpeaa)DE-He213 OHSS (dpeaa)DE-He213 Hasan, Eman Anwar aut Ali, Eman Ahmed aut Eltabakh, Ahmed Abdelkader aut Enthalten in Middle East Fertility Society journal [S.l.] : Elsevier, 2004 24(2019), 1 vom: 05. Sept. (DE-627)494831642 (DE-600)2196955-3 2090-3251 nnns volume:24 year:2019 number:1 day:05 month:09 https://dx.doi.org/10.1186/s43043-019-0002-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_206 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 24 2019 1 05 09 |
| allfieldsSound |
10.1186/s43043-019-0002-1 doi (DE-627)SPR038849267 (SPR)s43043-019-0002-1-e DE-627 ger DE-627 rakwb eng Behery, Mohamed Atef verfasserin aut Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2019 Background Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5–10% of women of reproductive age. The syndrome is surrounded by controversies regarding both its diagnosis and treatment. The introduction of long-acting GnRH agonists in the late 1980s revolutionized the approach to ovarian stimulation in assisted reproductive technologies by providing the means to downregulate endogenous pituitary gonadotropin secretion and thereby prevent a premature luteinizing hormone surge during exogenous gonadotropin stimulation. The relatively recent introduction of GnRH antagonists in clinical practice has provided another option for ovarian stimulation in IVF. The purpose of this study was to compare the efficacy of the fixed GnRH antagonist vs. GnRH agonist long protocol in patients with polycystic ovary syndrome treated by ICSI. Results There is a statistically significant difference between both groups in view of the received dose of gonadotrophin (1901.7 ± 400.6 vs. 1789 ± 368 with p = .004) and duration of stimulation (11.3 ± 0.8 vs. 10.3 ± 1.1 with p = .017). There is no significant difference between both groups in view of pregnancy outcome (37% vs. 32% with p = .125). There is a significant difference between both groups in view of ovarian hyperstimulation syndrome (OHSS) incidence where the rates were 15%, 6%, and 1.5% vs. 4.5%, 2.5%, and .05% with p = 0.04 for mild, moderate, and severe, respectively, form of OHSS in group 1 and group 2. Conclusion The antagonist protocol may be the preferred stimulation protocol for PCOS patients treated by ICSI in view of the reduction of OHSS incidence rates without compromising the pregnancy outcome. PCO (dpeaa)DE-He213 GnRH agonist (dpeaa)DE-He213 GnRH antagonist (dpeaa)DE-He213 ICSI (dpeaa)DE-He213 OHSS (dpeaa)DE-He213 Hasan, Eman Anwar aut Ali, Eman Ahmed aut Eltabakh, Ahmed Abdelkader aut Enthalten in Middle East Fertility Society journal [S.l.] : Elsevier, 2004 24(2019), 1 vom: 05. Sept. (DE-627)494831642 (DE-600)2196955-3 2090-3251 nnns volume:24 year:2019 number:1 day:05 month:09 https://dx.doi.org/10.1186/s43043-019-0002-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_206 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 24 2019 1 05 09 |
| language |
English |
| source |
Enthalten in Middle East Fertility Society journal 24(2019), 1 vom: 05. Sept. volume:24 year:2019 number:1 day:05 month:09 |
| sourceStr |
Enthalten in Middle East Fertility Society journal 24(2019), 1 vom: 05. Sept. volume:24 year:2019 number:1 day:05 month:09 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
PCO GnRH agonist GnRH antagonist ICSI OHSS |
| isfreeaccess_bool |
true |
| container_title |
Middle East Fertility Society journal |
| authorswithroles_txt_mv |
Behery, Mohamed Atef @@aut@@ Hasan, Eman Anwar @@aut@@ Ali, Eman Ahmed @@aut@@ Eltabakh, Ahmed Abdelkader @@aut@@ |
| publishDateDaySort_date |
2019-09-05T00:00:00Z |
| hierarchy_top_id |
494831642 |
| id |
SPR038849267 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR038849267</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519164958.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s43043-019-0002-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR038849267</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s43043-019-0002-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Behery, Mohamed Atef</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2019</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5–10% of women of reproductive age. The syndrome is surrounded by controversies regarding both its diagnosis and treatment. The introduction of long-acting GnRH agonists in the late 1980s revolutionized the approach to ovarian stimulation in assisted reproductive technologies by providing the means to downregulate endogenous pituitary gonadotropin secretion and thereby prevent a premature luteinizing hormone surge during exogenous gonadotropin stimulation. The relatively recent introduction of GnRH antagonists in clinical practice has provided another option for ovarian stimulation in IVF. The purpose of this study was to compare the efficacy of the fixed GnRH antagonist vs. GnRH agonist long protocol in patients with polycystic ovary syndrome treated by ICSI. Results There is a statistically significant difference between both groups in view of the received dose of gonadotrophin (1901.7 ± 400.6 vs. 1789 ± 368 with p = .004) and duration of stimulation (11.3 ± 0.8 vs. 10.3 ± 1.1 with p = .017). There is no significant difference between both groups in view of pregnancy outcome (37% vs. 32% with p = .125). There is a significant difference between both groups in view of ovarian hyperstimulation syndrome (OHSS) incidence where the rates were 15%, 6%, and 1.5% vs. 4.5%, 2.5%, and .05% with p = 0.04 for mild, moderate, and severe, respectively, form of OHSS in group 1 and group 2. Conclusion The antagonist protocol may be the preferred stimulation protocol for PCOS patients treated by ICSI in view of the reduction of OHSS incidence rates without compromising the pregnancy outcome.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PCO</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">GnRH agonist</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">GnRH antagonist</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ICSI</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">OHSS</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hasan, Eman Anwar</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ali, Eman Ahmed</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eltabakh, Ahmed Abdelkader</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Middle East Fertility Society journal</subfield><subfield code="d">[S.l.] : Elsevier, 2004</subfield><subfield code="g">24(2019), 1 vom: 05. Sept.</subfield><subfield code="w">(DE-627)494831642</subfield><subfield code="w">(DE-600)2196955-3</subfield><subfield code="x">2090-3251</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1</subfield><subfield code="g">day:05</subfield><subfield code="g">month:09</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s43043-019-0002-1</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2019</subfield><subfield code="e">1</subfield><subfield code="b">05</subfield><subfield code="c">09</subfield></datafield></record></collection>
|
| author |
Behery, Mohamed Atef |
| spellingShingle |
Behery, Mohamed Atef misc PCO misc GnRH agonist misc GnRH antagonist misc ICSI misc OHSS Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study |
| authorStr |
Behery, Mohamed Atef |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)494831642 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2090-3251 |
| topic_title |
Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study PCO (dpeaa)DE-He213 GnRH agonist (dpeaa)DE-He213 GnRH antagonist (dpeaa)DE-He213 ICSI (dpeaa)DE-He213 OHSS (dpeaa)DE-He213 |
| topic |
misc PCO misc GnRH agonist misc GnRH antagonist misc ICSI misc OHSS |
| topic_unstemmed |
misc PCO misc GnRH agonist misc GnRH antagonist misc ICSI misc OHSS |
| topic_browse |
misc PCO misc GnRH agonist misc GnRH antagonist misc ICSI misc OHSS |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Middle East Fertility Society journal |
| hierarchy_parent_id |
494831642 |
| hierarchy_top_title |
Middle East Fertility Society journal |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)494831642 (DE-600)2196955-3 |
| title |
Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study |
| ctrlnum |
(DE-627)SPR038849267 (SPR)s43043-019-0002-1-e |
| title_full |
Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study |
| author_sort |
Behery, Mohamed Atef |
| journal |
Middle East Fertility Society journal |
| journalStr |
Middle East Fertility Society journal |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
txt |
| author_browse |
Behery, Mohamed Atef Hasan, Eman Anwar Ali, Eman Ahmed Eltabakh, Ahmed Abdelkader |
| container_volume |
24 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Behery, Mohamed Atef |
| doi_str_mv |
10.1186/s43043-019-0002-1 |
| title_sort |
comparative study between agonist and antagonist protocols in pcos patients undergoing icsi: a cross-sectional study |
| title_auth |
Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study |
| abstract |
Background Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5–10% of women of reproductive age. The syndrome is surrounded by controversies regarding both its diagnosis and treatment. The introduction of long-acting GnRH agonists in the late 1980s revolutionized the approach to ovarian stimulation in assisted reproductive technologies by providing the means to downregulate endogenous pituitary gonadotropin secretion and thereby prevent a premature luteinizing hormone surge during exogenous gonadotropin stimulation. The relatively recent introduction of GnRH antagonists in clinical practice has provided another option for ovarian stimulation in IVF. The purpose of this study was to compare the efficacy of the fixed GnRH antagonist vs. GnRH agonist long protocol in patients with polycystic ovary syndrome treated by ICSI. Results There is a statistically significant difference between both groups in view of the received dose of gonadotrophin (1901.7 ± 400.6 vs. 1789 ± 368 with p = .004) and duration of stimulation (11.3 ± 0.8 vs. 10.3 ± 1.1 with p = .017). There is no significant difference between both groups in view of pregnancy outcome (37% vs. 32% with p = .125). There is a significant difference between both groups in view of ovarian hyperstimulation syndrome (OHSS) incidence where the rates were 15%, 6%, and 1.5% vs. 4.5%, 2.5%, and .05% with p = 0.04 for mild, moderate, and severe, respectively, form of OHSS in group 1 and group 2. Conclusion The antagonist protocol may be the preferred stimulation protocol for PCOS patients treated by ICSI in view of the reduction of OHSS incidence rates without compromising the pregnancy outcome. © The Author(s) 2019 |
| abstractGer |
Background Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5–10% of women of reproductive age. The syndrome is surrounded by controversies regarding both its diagnosis and treatment. The introduction of long-acting GnRH agonists in the late 1980s revolutionized the approach to ovarian stimulation in assisted reproductive technologies by providing the means to downregulate endogenous pituitary gonadotropin secretion and thereby prevent a premature luteinizing hormone surge during exogenous gonadotropin stimulation. The relatively recent introduction of GnRH antagonists in clinical practice has provided another option for ovarian stimulation in IVF. The purpose of this study was to compare the efficacy of the fixed GnRH antagonist vs. GnRH agonist long protocol in patients with polycystic ovary syndrome treated by ICSI. Results There is a statistically significant difference between both groups in view of the received dose of gonadotrophin (1901.7 ± 400.6 vs. 1789 ± 368 with p = .004) and duration of stimulation (11.3 ± 0.8 vs. 10.3 ± 1.1 with p = .017). There is no significant difference between both groups in view of pregnancy outcome (37% vs. 32% with p = .125). There is a significant difference between both groups in view of ovarian hyperstimulation syndrome (OHSS) incidence where the rates were 15%, 6%, and 1.5% vs. 4.5%, 2.5%, and .05% with p = 0.04 for mild, moderate, and severe, respectively, form of OHSS in group 1 and group 2. Conclusion The antagonist protocol may be the preferred stimulation protocol for PCOS patients treated by ICSI in view of the reduction of OHSS incidence rates without compromising the pregnancy outcome. © The Author(s) 2019 |
| abstract_unstemmed |
Background Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5–10% of women of reproductive age. The syndrome is surrounded by controversies regarding both its diagnosis and treatment. The introduction of long-acting GnRH agonists in the late 1980s revolutionized the approach to ovarian stimulation in assisted reproductive technologies by providing the means to downregulate endogenous pituitary gonadotropin secretion and thereby prevent a premature luteinizing hormone surge during exogenous gonadotropin stimulation. The relatively recent introduction of GnRH antagonists in clinical practice has provided another option for ovarian stimulation in IVF. The purpose of this study was to compare the efficacy of the fixed GnRH antagonist vs. GnRH agonist long protocol in patients with polycystic ovary syndrome treated by ICSI. Results There is a statistically significant difference between both groups in view of the received dose of gonadotrophin (1901.7 ± 400.6 vs. 1789 ± 368 with p = .004) and duration of stimulation (11.3 ± 0.8 vs. 10.3 ± 1.1 with p = .017). There is no significant difference between both groups in view of pregnancy outcome (37% vs. 32% with p = .125). There is a significant difference between both groups in view of ovarian hyperstimulation syndrome (OHSS) incidence where the rates were 15%, 6%, and 1.5% vs. 4.5%, 2.5%, and .05% with p = 0.04 for mild, moderate, and severe, respectively, form of OHSS in group 1 and group 2. Conclusion The antagonist protocol may be the preferred stimulation protocol for PCOS patients treated by ICSI in view of the reduction of OHSS incidence rates without compromising the pregnancy outcome. © The Author(s) 2019 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_206 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 |
| container_issue |
1 |
| title_short |
Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study |
| url |
https://dx.doi.org/10.1186/s43043-019-0002-1 |
| remote_bool |
true |
| author2 |
Hasan, Eman Anwar Ali, Eman Ahmed Eltabakh, Ahmed Abdelkader |
| author2Str |
Hasan, Eman Anwar Ali, Eman Ahmed Eltabakh, Ahmed Abdelkader |
| ppnlink |
494831642 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1186/s43043-019-0002-1 |
| up_date |
2024-07-03T20:21:29.247Z |
| _version_ |
1803590659472359424 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR038849267</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519164958.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s43043-019-0002-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR038849267</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s43043-019-0002-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Behery, Mohamed Atef</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2019</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5–10% of women of reproductive age. The syndrome is surrounded by controversies regarding both its diagnosis and treatment. The introduction of long-acting GnRH agonists in the late 1980s revolutionized the approach to ovarian stimulation in assisted reproductive technologies by providing the means to downregulate endogenous pituitary gonadotropin secretion and thereby prevent a premature luteinizing hormone surge during exogenous gonadotropin stimulation. The relatively recent introduction of GnRH antagonists in clinical practice has provided another option for ovarian stimulation in IVF. The purpose of this study was to compare the efficacy of the fixed GnRH antagonist vs. GnRH agonist long protocol in patients with polycystic ovary syndrome treated by ICSI. Results There is a statistically significant difference between both groups in view of the received dose of gonadotrophin (1901.7 ± 400.6 vs. 1789 ± 368 with p = .004) and duration of stimulation (11.3 ± 0.8 vs. 10.3 ± 1.1 with p = .017). There is no significant difference between both groups in view of pregnancy outcome (37% vs. 32% with p = .125). There is a significant difference between both groups in view of ovarian hyperstimulation syndrome (OHSS) incidence where the rates were 15%, 6%, and 1.5% vs. 4.5%, 2.5%, and .05% with p = 0.04 for mild, moderate, and severe, respectively, form of OHSS in group 1 and group 2. Conclusion The antagonist protocol may be the preferred stimulation protocol for PCOS patients treated by ICSI in view of the reduction of OHSS incidence rates without compromising the pregnancy outcome.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PCO</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">GnRH agonist</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">GnRH antagonist</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ICSI</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">OHSS</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hasan, Eman Anwar</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ali, Eman Ahmed</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eltabakh, Ahmed Abdelkader</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Middle East Fertility Society journal</subfield><subfield code="d">[S.l.] : Elsevier, 2004</subfield><subfield code="g">24(2019), 1 vom: 05. Sept.</subfield><subfield code="w">(DE-627)494831642</subfield><subfield code="w">(DE-600)2196955-3</subfield><subfield code="x">2090-3251</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1</subfield><subfield code="g">day:05</subfield><subfield code="g">month:09</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s43043-019-0002-1</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2019</subfield><subfield code="e">1</subfield><subfield code="b">05</subfield><subfield code="c">09</subfield></datafield></record></collection>
|
| score |
7.4003716 |